最新临床试验：伊布替尼和双珠单抗联合或不联合维奈托克治疗老年慢性淋巴细胞白血病

这是经美国国家癌症研究所批准的一项多中心三期临床随机对照试验，目的是研究了伊布替尼和双珠单抗联合或不联合维奈托克治疗老年慢性淋巴细胞白血病的疗效。伊布替尼可能通过阻断细胞生长所需的某些酶来阻止癌细胞的生长。用双珠单抗进行免疫治疗，可能引起机体免疫系统的变化，并可能干扰癌细胞的生长和扩散能力。化疗中使用的药物，如维奈托克，以不同的方式阻止癌细胞的生长，或者杀死癌细胞，阻止癌细胞分裂，或者阻止癌细胞扩散。给予伊布替尼和双珠单抗联合维奈托克治疗慢性淋巴细胞白血病可能效果更好。

该临床试验在全美302家医院进行开展。

This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax works in treating older patients with untreated chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab, may induce changes in body’s immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib and obinutuzumab with venetoclax may work better at treating chronic lymphocytic leukemia.

Trial IDs